A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 In

Tucker, Thomas J.; Embrey, Mark W.; Alleyne, Candice; Amin, Rupesh P.; Bass, Alan; Bhatt, Bhavana; Bianchi, Elisabetta; Branca, Danila; Bueters, Tjerk; Buist, Nicole; Ha, Sookhee N.; Hafey, Mike; He, Huaibing; Higgins, John; Johns, Douglas G.; Kerekes, Angela D.; Koeplinger, Kenneth A.; Kuethe, Jeffrey T.; Li, Nianyu; Murphy, BethAnn; Orth, Peter; Salowe, Scott; Shahripour, Aurash; Tracy, Rodger; Wang, Weixun; Wu, Chengwei; Xiong, Yusheng; Zokian, Hratch J.; Wood, Harold B.; Walji, Abbas

doi:10.1021/acs.jmedchem.1c01599

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 In

Journal Article · 01 October 2021 · J. Med. Chem.

DOI:https://doi.org/10.1021/acs.jmedchem.1c01599· OSTI ID:1844719

Tucker, Thomas J.; Embrey, Mark W.; Alleyne, Candice; Amin, Rupesh P.; Bass, Alan; Bhatt, Bhavana; Bianchi, Elisabetta; Branca, Danila; Bueters, Tjerk; Buist, Nicole; Ha, Sookhee N.; Hafey, Mike; He, Huaibing; Higgins, John; Johns, Douglas G.; Kerekes, Angela D.; Koeplinger, Kenneth A.; Kuethe, Jeffrey T.; Li, Nianyu; Murphy, BethAnn more »

Research Organization:: Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)

Sponsoring Organization:: DOE - Office Of Science; INDUSTRY

OSTI ID:: 1844719

Journal Information:: J. Med. Chem., Journal Name: J. Med. Chem. Journal Issue: (22) Vol. 64

Country of Publication:: United States

Language:: ENGLISH

References (34)

Determining target engagement in living systems Simon, Gabriel M.; Niphakis, Micah J.; Cravatt, Benjamin F. Nature Chemical Biology, Vol. 9, Issue 4 https://doi.org/10.1038/nchembio.1211	journal	March 2013
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists Zhang, Yingnan; Ultsch, Mark; Skelton, Nicholas J. Nature Structural & Molecular Biology, Vol. 24, Issue 10 https://doi.org/10.1038/nsmb.3453	journal	August 2017
Features and development of Coot Emsley, P.; Lohkamp, B.; Scott, W. G. Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 4 https://doi.org/10.1107/S0907444910007493	journal	March 2010
Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor Tombling, Benjamin J.; Lammi, Carmen; Lawrence, Nicole Journal of Medicinal Chemistry, Vol. 64, Issue 5 https://doi.org/10.1021/acs.jmedchem.0c01766	journal	December 2020
PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol Wang, Yan; Liu, Zhao-Peng Mini-Reviews in Medicinal Chemistry, Vol. 19, Issue 2 https://doi.org/10.2174/1389557518666180423111442	journal	December 2018
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents Londregan, Allyn T.; Wei, Liuqing; Xiao, Jun Journal of Medicinal Chemistry, Vol. 61, Issue 13 https://doi.org/10.1021/acs.jmedchem.8b00650	journal	January 2018
Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies McCartney, Fiona; Jannin, Vincent; Chevrier, Stéphanie Journal of Controlled Release, Vol. 310 https://doi.org/10.1016/j.jconrel.2019.08.008	journal	September 2019
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design Alleyne, Candice; Amin, Rupesh P.; Bhatt, Bhavana Journal of Medicinal Chemistry, Vol. 63, Issue 22 https://doi.org/10.1021/acs.jmedchem.0c01084	journal	November 2020
PCSK9: A Key Modulator of Cardiovascular Health Seidah, Nabil G.; Awan, Zuhier; Chrétien, Michel Circulation Research, Vol. 114, Issue 6 https://doi.org/10.1161/CIRCRESAHA.114.301621	journal	March 2014
Abstract 7: A Subcutaneous, Potent and Durable RNAi Platform Targeting Metabolic Diseases, Genes PCSK9, ApoC3 and ANGPLT3 Fitzgerald, Kevin; Borodovsky, Anna; Querbes, William Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 34, Issue suppl_1 https://doi.org/10.1161/atvb.34.suppl_1.7	journal	May 2014
Small Molecule Inhibitors of the PCSK9·LDLR Interaction Taechalertpaisarn, Jaru; Zhao, Bosheng; Liang, Xiaowen Journal of the American Chemical Society, Vol. 140, Issue 9 https://doi.org/10.1021/jacs.7b09360	journal	January 2018
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist Bucheit, John D.; Pamulapati, Lauren G.; Carter, Nicole Diabetes Technology & Therapeutics, Vol. 22, Issue 1 https://doi.org/10.1089/dia.2019.0185	journal	January 2020
Role of liver in the synthesis of cholesterol and the clearance of low density lipoproteins in the cynomolgus monkey Turley, S. D.; Spady, D. K.; Dietschy, J. M. Journal of Lipid Research, Vol. 36, Issue 1 https://doi.org/10.1016/S0022-2275(20)39755-8	journal	January 1995
Labelled chemical probes for demonstrating direct target engagement in living systems Prevet, Hugues; Collins, Ian Future Medicinal Chemistry, Vol. 11, Issue 10 https://doi.org/10.4155/fmc-2018-0370	journal	May 2019
Overview of the CCP 4 suite and current developments Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D. Acta Crystallographica Section D Biological Crystallography, Vol. 67, Issue 4 https://doi.org/10.1107/S0907444910045749	journal	March 2011
Small molecules as inhibitors of PCSK9: Current status and future challenges Xu, Shengtao; Luo, Shanshan; Zhu, Zheying European Journal of Medicinal Chemistry, Vol. 162 https://doi.org/10.1016/j.ejmech.2018.11.011	journal	January 2019
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab McDonagh, Marian; Peterson, Kim; Holzhammer, Brittany Journal of Managed Care & Specialty Pharmacy, Vol. 22, Issue 6 https://doi.org/10.18553/jmcp.2016.22.6.641	journal	June 2016
Importance of cynomolgus monkeys in development of monoclonal antibody drugs Iwasaki, Kazuhide; Uno, Yasuhiro; Utoh, Masahiro Drug Metabolism and Pharmacokinetics, Vol. 34, Issue 1 https://doi.org/10.1016/j.dmpk.2018.02.003	journal	February 2019
Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions Shitara, Yoshihisa Drug Metabolism and Pharmacokinetics, Vol. 26, Issue 3 https://doi.org/10.2133/dmpk.DMPK-10-RV-094	journal	January 2011
Automated ligand placement and refinement with a combined force field and shape potential Wlodek, S.; Skillman, A. G.; Nicholls, A. Acta Crystallographica Section D Biological Crystallography, Vol. 62, Issue 7 https://doi.org/10.1107/S0907444906016076	journal	June 2006
Labrasol® and Salts of Medium-Chain Fatty Acids Can Be Combined in Low Concentrations to Increase the Permeability of a Macromolecule Marker Across Isolated Rat Intestinal Mucosae Heade, Joanne; Maher, Sam; Bleiel, Sinead B. Journal of Pharmaceutical Sciences, Vol. 107, Issue 6 https://doi.org/10.1016/j.xphs.2018.02.012	journal	June 2018
Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance Ali, Akbar; Aydin, Cihan; Gildemeister, Reinhold ACS Chemical Biology, Vol. 8, Issue 7 https://doi.org/10.1021/cb400100g	journal	May 2013
Genetic and Metabolic Determinants of Plasma PCSK9 Levels Lakoski, Susan G.; Lagace, Thomas A.; Cohen, Jonathan C. The Journal of Clinical Endocrinology & Metabolism, Vol. 94, Issue 7 https://doi.org/10.1210/jc.2009-0141	journal	July 2009
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates Chan, J. C. Y.; Piper, D. E.; Cao, Q. Proceedings of the National Academy of Sciences, Vol. 106, Issue 24 https://doi.org/10.1073/pnas.0903849106	journal	May 2009
Role of Bile in Infectious Disease: the Gall of 7α-Dehydroxylating Gut Bacteria Savidge, Tor; Sorg, Joseph A. Cell Chemical Biology, Vol. 26, Issue 1 https://doi.org/10.1016/j.chembiol.2018.12.010	journal	January 2019
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist Powell, Jason; Piszczatoski, Chris; Taylor, James R. Clinical Therapeutics, Vol. 42, Issue 10 https://doi.org/10.1016/j.clinthera.2020.07.017	journal	October 2020
2,4,6-Tri-isopropylbenzenesulphonyl hydrazide: A convenient source of di-imide Cusack, N. J.; Reese, C. B.; Risius, A. C. Tetrahedron, Vol. 32, Issue 17 https://doi.org/10.1016/0040-4020(76)85128-9	journal	January 1976
Assessing the Utility of In Vitro Screening Tools for Predicting Bio-Performance of Oral Peptide Delivery Gadgil, Prajakta; Alleyne, Candice; Feng, Kung-I Pharmaceutical Research, Vol. 36, Issue 10 https://doi.org/10.1007/s11095-019-2682-8	journal	August 2019
Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy Lavecchia, Antonio; Cerchia, Carmen Future Medicinal Chemistry, Vol. 11, Issue 5 https://doi.org/10.4155/fmc-2018-0294	journal	March 2019
Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor Zhang, Yingnan; Eigenbrot, Charles; Zhou, Lijuan Journal of Biological Chemistry, Vol. 289, Issue 2 https://doi.org/10.1074/jbc.M113.514067	journal	November 2013
Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers Fattah, Sarinj; Ismaiel, Mohamed; Murphy, Brenda European Journal of Pharmaceutical Sciences, Vol. 154 https://doi.org/10.1016/j.ejps.2020.105509	journal	November 2020
Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic Stucchi, Mattia; Grazioso, Giovanni; Lammi, Carmen Organic & Biomolecular Chemistry, Vol. 14, Issue 41 https://doi.org/10.1039/C6OB01642A	journal	January 2016
Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates Liang, Hong; Chaparro-Riggers, Javier; Strop, Pavel Journal of Pharmacology and Experimental Therapeutics, Vol. 340, Issue 2 https://doi.org/10.1124/jpet.111.187419	journal	October 2011
Mechanisms of histamine release by compound 48/80 Rothschild, A. M. British Journal of Pharmacology, Vol. 38, Issue 1 https://doi.org/10.1111/j.1476-5381.1970.tb10354.x	journal	January 1970

Similar Records

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Scree

Journal Article · 2020 · J. Med. Chem. · OSTI ID:1834858

Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase [gamma] Inhibitors

Journal Article · 2013 · J. Med. Chem. · OSTI ID:1093490

Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors

Journal Article · 2012 · Journal of Medicinal Chemistry · OSTI ID:1495458

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 In

Citation Formats

References (34)

Similar Records

Related Subjects